Stability-indicating micellar liquid chromatography method for three novel derivatives of zidovudine in aqueous and simulated gastric and intestinal fluids matrices

Journal of Chromatography A

Volumn 1218, Issue 18, 2011, Pages 2540-2545

  Raviolo, Mónica A ^a   Esteve Romero, Josep ^b   Briñón, Margarita C ^a  

^a UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^b UNIVERSITAT JAUME I   (Spain)

Author keywords

Gastric and intestinal matrices; Micellar liquid chromatography; Stability indicating HPLC methods; Zidovudine derivatives

Indexed keywords

1-BUTANOL; ACID GROUPS; ANTI-HIV AGENTS; COMMERCIALISATION; DEGRADATION PRODUCTS; GASTRIC AND INTESTINAL MATRICES; GASTRIC FLUIDS; INTESTINAL FLUID; KINETIC CONSTANT; LIFE-TIMES; MICELLAR LIQUID CHROMATOGRAPHY; MOBILE PHASE; PSEUDO-FIRST ORDER KINETICS; REFERENCE METHOD; RETENTION TIME; SODIUM DODECYL SULPHATE; STABILITY STUDY; VALIDATED METHODS; WORK STUDY; ZIDOVUDINE DERIVATIVES;

AMINO ACIDS; CHROMATOGRAPHY; DEGRADATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUIDS; RATE CONSTANTS; SODIUM;

STABILITY;

ACID ZIDOVUDINE; BUTANOL; DODECYL SULFATE SODIUM; LEUCINE ZIDOVUDINE; UNCLASSIFIED DRUG; VALINE ZIDOVUDINE; ZIDOVUDINE; ZIDOVUDINE DERIVATIVE;

ACCURACY; AQUEOUS SOLUTION; ARTICLE; CALIBRATION; CONTROLLED STUDY; DRUG DEGRADATION; DRUG HALF LIFE; DRUG STABILITY; INTESTINE FLUID; MICELLAR LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PRODUCT RECOVERY; SIMULATION; STOMACH JUICE; VALIDATION PROCESS;

BODY FLUIDS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; GASTRIC JUICE; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINES; MICELLES; MODELS, BIOLOGICAL; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; ZIDOVUDINE;

EID: 79954417135     PISSN: 00219673     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chroma.2011.02.018     Document Type: Article

References (39)

1. Kerns E.H. J. Pharm. Sci. 2001, 90:1838.
2. Chen X.Q., Antman M.D., Gesenberg C., Gudmundsson O.S. AAPS J. 2006, 8:E402.
3. Guidance for Industry Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System 2000, U.S. Department of Health and Human Services. Food and Drug Administration, Rockville, MD, USA.
4. Cihlar T., Ray A.S. Antiviral Res. 2010, 85:39.
5. Wensing A.M.J., van Maarseveen N.M., Nijhuis M. Antiviral Res. 2010, 85:59.
6. Béthune M.P. Antiviral Res. 2010, 85:75.
7. Tilton J.C., Doms R.W. Antiviral Res. 2010, 85:91.
8. McColl D.J., Chen X. Antiviral Res. 2010, 85:101.
9. Adamson C.S., Freed E.O. Antiviral Res. 2010, 85:119.
10. Buckheit R.W., Watson K.M., Morrow K.M., Ham A.S. Antiviral Res. 2010, 85:142.
11. Gallo R.C., Salahuddin S.Z., Popovic M., Shearer G.M., Kaplan M., Haynes B.F., Palker T.J., Redfield R., Oleske J., Safai B., White G., Foster P., Markham P.D. Science 1984, 224:500.
12. Mitsuya H., Weihold K.J., Furman P.A., Clain M.H., Nusinoff-Lehrman S., Gallo R.C., Bolognesi D.P., Barry D.W., Broder S. Proc. Natl. Acad. Sci. U.S.A. 1985, 82:7096.
13. Gill P.S., Rarick M., Brynes R.K., Cauey D., Loureiro C., Levine A.M. Ann. Intern. Med. 1987, 107:502.
14. Chariot P., Drogou I., Lacroix-Szmania I., Eliezer-Vanerot M.C., Chazaud B., Lombes A., Schaeffer A., Zafrani E.S. J. Hepatol. 1999, 30:156.
15. Groothuis D.R., Levy R.M. J. Neurovirol. 1997, 3:387.
16. Anderson P.L., Kakuda T.N., Fletcher C.V. Pharmacotherapy: A Pathophysiologic Approach 2008, pp. 2077. McGraw Hills Publishers, Australia. J.T. DiPiro, R.L. Talbert, G.C. Yee, G.R. Matzke, B.G. Wells, L.M. Posey (Eds.).
17. Resetar A., Spector T. Biochem. Pharmacol. 1989, 38:1389.
18. Dalakas M.C., Illa I., Pezeshkpour G.H., Laukaitis J.P., Cohen B., Griffin J.L., Engl.F N. J. Med. 1990, 322:1098.
19. Miller J., Carr A., Smith D., Emergy S., Law M.G., Grey P., Cooper D.A. AIDS 2000, 14:2406.
20. Clavel F., Hance A.J., Engl.F N. J. Med. 2004, 350:1023.
21. Calogeropoulou T., Detsi A., Lekkas E., Koufaki M. Curr. Top. Med. Chem. 2003, 3:1467.
22. Parang K., Wiebe L.I., Knaus E.E. Curr. Med. Chem. 2000, 7:995.
23. Moroni G.N., Bogdanov P.M., Briñón M.C. Nucleosides Nucleotides Nucleic Acids 2002, 21:231.
24. Moroni G.N., Quevedo M.A., Ravetti S., Briñón M.C. J. Liquid Chromatogr. Relat. Technol. 2002, 25:1345.
25. Turk G., Moroni G.N., Pampuro S., Briñón M.C., Salomón H. Int. J. Antimicrob. Agents 2002, 20:282.
26. Pochopin N.L., Charman W.N., Stella V.J. Int. J. Pharm. 1995, 121:157.
27. Sun Y., Sun J., Sun J., Shi S., Jing Y., Yin S., Chen Y., Li G., Xu Y., He Z. Mol. Pharm. 2008, 6:315.
28. Quevedo M.A., Moroni G.N., Briñón M.C. Biochem. Biophys. Res. Commun. 2001, 288:954.
29. Quevedo M.A., Ribone S., Moroni G.N., Briñón M.C. Bioorg. Med. Chem. 2008, 16:2779.
30. Quevedo M.A., Briñón M.C. Antiviral Res. 2009, 83:103.
31. Esteve-Romero J., Carda-Broch S., Gil-Agustí M., Capella-Peiró M.E., Bose D. TRAC 2005, 24:75.
32. Raviolo M.A., Casas-Breva I., Esteve-Romero J. J. Chromatogr. A 2009, 1216:3546.
33. Test Test solutions United States Pharmacopoeia 32/National Formulary 27 2009.
34. Torres-Lapasió J.R. Michrom Software 2000, Marcel Dekker, NY, USA.
35. Guidance for Industry Bioanalytical, Method Validation 2001, U.S. Department of Health and Human Services. Food and Drug Administration, Rockville, MD, USA.
36. MarvinSketch 5.3.8. 1998-2010, ChemAxon Ltd.
37. Mendes E., Furtado T., Neres J., Iley J., Jarvinen T., Rautio J., Moreira R. Bioorg. Med. Chem. 2002, 10:809.
38. Bowden K., Izadi J. Eur. J. Med. Chem. 1997, 32:987.
39. Fersht A.R., Kirby A.J. J. Am. Chem. Soc. 1968, 90:5818.